Matthew L. Sherman
About
Matthew L. Sherman is a scholar working on Molecular Biology, Hematology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Matthew L. Sherman has authored 134 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Molecular Biology, 34 papers in Hematology and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matthew L. Sherman's work include TGF-β signaling in diseases (19 papers), Gastrointestinal Tumor Research and Treatment (12 papers) and Acute Myeloid Leukemia Research (12 papers). Matthew L. Sherman is often cited by papers focused on TGF-β signaling in diseases (19 papers), Gastrointestinal Tumor Research and Treatment (12 papers) and Acute Myeloid Leukemia Research (12 papers). Matthew L. Sherman collaborates with scholars based in United States, Germany and Netherlands. Matthew L. Sherman's co-authors include Donald Küfe, Michael B. Atkins, Janice P. Dutcher, Rakesh Datta, David R. Spriggs, D Kufe, Kenneth M. Attie, K. Imamura, Dawn Wilson and John L. Ryan and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.
In The Last Decade
Matthew L. Sherman
130 papers receiving 7.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Matthew L. Sherman United States | 41 | 3.2k | 2.2k | 2.1k | 1.5k | 945 | 134 | 7.8k | ||
| Lars Rönnstrand Sweden | 54 | 5.9k 1.8× | 2.0k 0.9× | 2.0k 0.9× | 1.9k 1.2× | 727 0.8× | 173 | 10.2k | ||
| Walter C. Darbonne United States | 26 | 2.7k 0.8× | 1.5k 0.7× | 1.9k 0.9× | 1.4k 0.9× | 494 0.5× | 46 | 6.1k | ||
| Louis M. Pelus United States | 47 | 2.5k 0.8× | 2.3k 1.1× | 1.8k 0.9× | 2.0k 1.3× | 411 0.4× | 159 | 6.3k | ||
| Osamu Miura Japan | 43 | 2.7k 0.8× | 2.3k 1.1× | 3.4k 1.6× | 1.8k 1.2× | 421 0.4× | 243 | 7.4k | ||
| Tsuneyo Mimori Japan | 59 | 3.2k 1.0× | 3.2k 1.4× | 938 0.4× | 847 0.6× | 1.8k 1.9× | 396 | 12.9k | ||
| Wun-Jing Kuang United States | 12 | 5.8k 1.8× | 2.0k 0.9× | 2.5k 1.2× | 1.7k 1.1× | 1.2k 1.3× | 12 | 11.7k | ||
| Yoshiaki Tomiyama Japan | 49 | 2.0k 0.6× | 2.0k 0.9× | 909 0.4× | 3.6k 2.3× | 717 0.8× | 275 | 8.3k | ||
| Masayoshi Harigai Japan | 46 | 1.5k 0.5× | 1.9k 0.9× | 1.1k 0.5× | 1.2k 0.8× | 1.5k 1.6× | 345 | 8.1k | ||
| Ulrich Dührsen Germany | 51 | 2.2k 0.7× | 3.2k 1.5× | 3.0k 1.4× | 3.1k 2.0× | 788 0.8× | 283 | 10.3k | ||
| Hiroaki Kataoka Japan | 47 | 4.0k 1.2× | 1.1k 0.5× | 1.9k 0.9× | 687 0.4× | 725 0.8× | 295 | 8.1k |
Countries citing papers authored by Matthew L. Sherman
Since
Specialization
Citations
This map shows the geographic impact of Matthew L. Sherman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew L. Sherman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew L. Sherman more than expected).
Fields of papers citing papers by Matthew L. Sherman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Matthew L. Sherman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew L. Sherman. The network helps show where Matthew L. Sherman may publish in the future.
Co-authorship network of co-authors of Matthew L. Sherman
This figure shows the co-authorship network connecting the top 25 collaborators of Matthew L. Sherman. A scholar is included among the top collaborators of Matthew L. Sherman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew L. Sherman. Matthew L. Sherman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Tap, William D., Vivek A. Bhadri, Silvia Stacchiotti, et al.. (2024). Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.. Journal of Clinical Oncology. 42(16_suppl). 11500–11500.
2.
Chandana, Sreenivasa R, Dale R. Shepard, Janice M. Mehnert, et al.. (2024). DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study.. Journal of Clinical Oncology. 42(16_suppl). TPS11587–TPS11587.
3.
Zalcberg, John, Robin L. Jones, Jean‐Yves Blay, et al.. (2024). Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.. Journal of Clinical Oncology. 42(3_suppl). 748–748.
4.
Tap, William D., Bryan D. Smith, Matthew L. Sherman, et al.. (2023). The MOTION Study: A Randomized, Phase III Study of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor. Future Oncology. 20(10). 593–601.
5.
Bauer, Sebastian, Robin L. Jones, Jean‐Yves Blay, et al.. (2022). Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology. 40(34). 3918–3928.
6.
Gelderblom, Hans, et al.. (2022). 475P Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update. Annals of Oncology. 33. S757–S758.
7.
Statland, Jeffrey, Anthony A. Amato, Elena Bravver, et al.. (2018). Preliminary Results from a Phase 2 Study to Evaluate ACE-083, a Local Muscle Therapeutic, in Patients with Facioscapulohumeral Muscular Dystrophy (S38.001). Neurology. 90(15_supplement).
8.
Voss, Martin H., Rupal S. Bhatt, Elizabeth R. Plimack, et al.. (2016). The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clinical Cancer Research. 23(14). 3557–3565.
9.
Giagounidis, Aristoteles, Uwe Platzbecker, Ulrich Germing, et al.. (2015). Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. Blood. 126(23). 92–92.
10.
Bendell, Johanna C., Michael S. Gordon, Herbert I. Hurwitz, et al.. (2013). Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer. Clinical Cancer Research. 20(2). 480–489.
11.
Sherman, Matthew L., Niels Borgstein, Dawn Wilson, et al.. (2013). Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women. The Journal of Clinical Pharmacology. 53(11). 1121–1130.
12.
Chan, Stephen, Alan N. Gordon, Robert E. Coleman, et al.. (2003). A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunology Immunotherapy. 52(4). 243–248.
13.
Neoptolemos, John P., Matthew L. Sherman, Andrew Stanley, et al.. (1996). Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution. British Journal of Cancer. 74(12). 2032–2035.
14.
Dezube, Bruce J., et al.. (1993). Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: A pilot study. Cancer Immunology Immunotherapy. 36(1). 57–60.
15.
Rhee, Myung S., et al.. (1993). Effect of a Novel Antifolate, Nα-(4-Amino-4-Deoxypteroyl)-Nδ-Hemiphthaloyl-L-Ornithbsfe (PT523), On Growth of H35 Rat Hepatoma and HEPG2 Human Hepatoma Cells. Advances in experimental medicine and biology. 338. 461–464.
16.
Clinton, Steven K., et al.. (1992). Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis.. PubMed Central. 140(2). 301–16.
17.
Datta, Rakesh, et al.. (1992). Transcriptional regulation of cytokine expression by diethyldithiocarbamate in human HL-60 promyelocytic leukemia cells. Biochemical Pharmacology. 44(2). 365–371.
18.
Datta, Rakesh, Dennis E. Hallahan, Surender Kharbanda, et al.. (1992). Involvement of reactive oxygen intermediates in the induction of c-jun gene transcription by ionizing radiation. Biochemistry. 31(35). 8300–8306.
19.
Bernstein, Steven H., Surender Kharbanda, Matthew L. Sherman, Richard M. Stone, & D Kufe. (1991). Inhibition of protein kinase C is associated with a decrease in c‐myc expression in human myeloid leukemia cells. FEBS Letters. 294(1-2). 73–76.
20.
Bernstein, Steven H., Matthew L. Sherman, Ralf Hass, et al.. (1991). Effects of hexamethylene bisacetamide on induction of monocytic differentiation of human U-937 myeloid leukemia cells. Biochemical Pharmacology. 42(2). 403–407.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Lars Rönnstrand Breakdown of academic impact, for papers by Walter C. Darbonne Breakdown of academic impact, for papers by Louis M. Pelus Breakdown of academic impact, for papers by Osamu Miura Breakdown of academic impact, for papers by Tsuneyo Mimori Breakdown of academic impact, for papers by Wun-Jing Kuang Breakdown of academic impact, for papers by Yoshiaki Tomiyama Breakdown of academic impact, for papers by Masayoshi Harigai Breakdown of academic impact, for papers by Ulrich Dührsen Breakdown of academic impact, for papers by Hiroaki Kataoka